** U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading
** J.P.Morgan upgrades to "overweight" from "neutral"; lifts PT from $9 to $12, ~42% upside to last close of $7.83
** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars
** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth
** Stock rated "buy" on avg; median PT is $11 - LSEG
** AMRX down 1.13% so far this year, as of Friday's close
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。